WeightWatchers relaunches around GLP-1 users

WeightWatchers has rebuilt its business around GLP-1 medications. Under chief executive Tara Comonte, the company relaunched its platform with prescribing through a program called Med+, added a track for people who already have a GLP-1 prescription from another provider, and rolled out new coaching tools tied to the drugs ^[1]. The overhaul, described in a WW release dated December 16, 2025, caps a year in which weight-loss businesses across the industry rebuilt themselves around semaglutide and tirzepatide ^[1].

Med+ pairs a prescription with WW's traditional behavioral program: food tracking, coaching, and community support. Licensed clinicians evaluate members and can prescribe FDA-approved brand medications, including Wegovy in both injection and pill form, Zepbound, Saxenda, and the orforglipron pill sold as Foundayo, along with metformin and naltrexone/bupropion ^[1]. Prescriptions are filled through WW's mail-order pharmacy partner, Carepoint, in Illinois ^[1]. WW does not offer compounded semaglutide or tirzepatide; third-party reviewers date its exit from compounded versions to around May 2025, months after the Food and Drug Administration declared the tirzepatide shortage resolved on December 19, 2024, and the semaglutide shortage resolved on February 21, 2025 ^[1].

WW's own figures, released alongside the relaunch, describe average body-weight loss of 21% at 12 months among Med+ members taking a GLP-1, based on company data from about 3,250 patients that has not been peer reviewed ^[1]. More than 70% of surveyed Med+ members said the program helps them minimize side effects, and a separate WW-commissioned survey found 90% of GLP-1 users want community support, according to the December 16, 2025 release ^[1]. For comparison, Zepbound's own prescribing information reports 20.9% mean weight loss at 72 weeks on the 15 mg dose in the SURMOUNT-1 trial, so WW's reported figure lines up with what the drug itself has shown in trials rather than demonstrating that WW's coaching adds extra weight loss ^[1]. Third-party review aggregators put WW's Trustpilot score at about 3.9 out of 5 across more than 1,660 reviews ^[1].

On pricing, Med+ membership was listed at $25 a month for the first two months on a 12-month plan, then $74 a month, with medication billed separately ^[1]. A new no-prescription track, called GLP-1 Success, was advertised at $20 a month for people who already have a GLP-1 prescription from elsewhere ^[1]. Medication costs on top of membership varied by drug and dose: cash-pay Zepbound through LillyDirect ran from $299 to $449 a month depending on dose, and Wegovy's self-pay pen and pill options ranged from $149 to $399 ^[1].

Why it matters for patients

For people already using or considering a GLP-1 drug, WW's relaunch adds another option that combines a prescription pathway with structured behavioral support, which may appeal to people who want tracking and coaching alongside medication rather than a bare prescription service ^[1]. But the reported 21% weight-loss figure comes from WW's own unreviewed data and closely matches what trials already show for Zepbound on its own, so it does not show that WW's coaching adds benefit beyond the drug itself ^[1]. WW's brand-only medication policy means people looking for lower-cost compounded semaglutide or tirzepatide will need to look elsewhere, since WW does not sell those versions ^[1]. As with any subscription health service, the all-in monthly cost combines a membership fee and a separate medication charge, and coverage depends on insurance status, since WW's insurance coordinators work with commercial plans only, not Medicare, Medicaid, or Kaiser ^[1].

What happens next

A reported WW pricing offer for new Med+ members was set to end September 8, 2026 ^[1]. Separately, a Medicare GLP-1 Bridge program, unrelated to WW, was described as running from July 1, 2026, through December 31, 2027, offering $50-a-month access to Zepbound, Wegovy, and Foundayo for eligible Medicare beneficiaries with prior authorization ^[1]. How WW's relaunched program performs against competitors offering similar prescribing and coaching, including Noom and Hims and Hers, is not yet known beyond the figures WW itself has released ^[1].